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Abstract
Objective: Despite decades of research on risk indicators of 
spontaneous preterm birth (PTB), reliable biomarkers are 
still not available to screen or diagnose high-risk pregnan-
cies. Several biomarkers in maternal and fetal compart-
ments have been mechanistically linked to PTB, but none 
of them are reliable predictors of pregnancy outcome. This 
systematic review was conducted to synthesize the knowl-
edge on PTB biomarkers identified using multiplex analysis.
Materials and methods: Three electronic databases 
(PubMed, EMBASE and Web of Science) were searched 
for studies in any language reporting the use of multiplex 
assays for maternal biomarkers associated with PTB pub-
lished from January 2005 to March 2014.
Results: Retrieved citations (3631) were screened, and rel-
evant studies (33) were selected for full-text reading. Ten 
studies were included in the review. Forty-two PTB-related 
proteins were reported, and RANTES and IL-10 (three 
studies) followed by MIP-1β, GM-CSF, Eotaxin, and TNF-RI 
(two studies) were reported more than once in maternal 
serum. However, results could not be combined due to 
heterogeneity in type of sample, study population, assay, 
and analysis methods.
Conclusion: By this systematic review, we conclude that 
multiplex assays are a potential technological advance-
ment for identifying biomarkers of PTB, although no sin-
gle or combination of biomarkers could be identified to 
predict PTB risk.
Keywords: Biological markers; cytokines; multiplex assay; 
prematurity.
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Introduction
Preterm birth (PTB; birth before 37 weeks’ gestation) is 
the leading cause of neonatal morbidity and mortality 
worldwide [1–5], yet little is known about its underlying 
etiology. PTB is a complex syndrome with multifactorial 
etiologies that can be broadly classified into two groups: 
(1) spontaneous PTB, which accounts for approximately 
70% of the preterm deliveries, and is further referred to, 
in this review, as PTB; and (2) provider-initiated PTB, also 
named iatrogenic PTB, which accounts for the remaining 
25% of preterm deliveries. The pathways leading to PTB 
are redundant and overlapping between etiologies; thus, 
understanding PTB initiators and effectors is difficult, pre-
cluding their use as risk predictors for this condition [6, 
7]. Development of new technologies and methodological 
approaches over the past decade has provided an impetus 
in the search for predictive and diagnostic PTB biomarkers; 
many of these biomarkers have been identified in mater-
nal-fetal compartments, including maternal blood, amni-
otic fluid, and cervicovaginal fluids. Still, there is no clear 
consensus on which biomarker(s) should be considered 
the best predictor(s) of PTB. The Preterm Birth Interna-
tional Collaborative (PREBIC; www.prebic.org) performed 
a systematic review of the literature on single maternal 
biomarkers for PTB [8]. The report identified 116 differ-
ent biomarkers in 217 studies published in the last four 
decades. Three other reviews on PTB biomarkers reached 
similar conclusions, supporting the concept that there are 
no single biomarkers able to reliably predict PTB [9–11]. As 
multiple and intricate pathways result in PTB, it is unlikely 
that a single biomarker will predict the risk of PTB.
These findings led to additional work by the PREBIC 
Biomarker Working Group, and a second systematic 
review examined panels of biomarkers identified through 
proteomic technologies [12], specifically through protein 
electrophoresis and mass spectrometry [matrix-assisted 
laser desorption/ionization (MALDI) or surface-enhanced 
laser desorption/ionization (SELDI)] protein profil-
ing. From a total of 64 dysregulated proteins identified, 
none of them were reproducible or capable of predicting 
PTB. As observed in single-biomarker studies, the use of 
technologically different assay platforms and analytical 
approaches contributed to a lack of reproducible data for 
identifying reliable PTB biomarkers, as did heterogeneity 
in study design, sampling, assay methods, and analysis. 
However, as an unbiased approach, a well-designed pro-
teomic study is still promising to yield novel biomarkers.
Technological advancements in the past decade have 
further modernized biomarker discovery. Multiplexed 
assays and quantitative protein microarrays have led to 
the publication of a large number of biomarker studies 
related to PTB. Advantages of multiplex technology 
include simultaneous analysis of a broad panel of bio-
markers chosen by investigators based on known biomo-
lecular pathways of preterm labor, use of a small sample 
volume, cost effectiveness, and minimal technological 
challenges compared to proteomics [13]. Several reports 
have been published in the past decade using multiplex 
platforms to report different PTB-related end phenotypes 
including intra-amniotic infection and inflammation, 
histological chorioamnionitis, and early onset neonatal 
sepsis in PTB [14–20]. Samples tested included maternal 
blood, amniotic and  cervicovaginal fluid, and umbilical 
cord blood.
PREBIC conducted this third systematic review to 
synthesize the knowledge on PTB biomarkers identified 
using multiplex approaches. We reviewed the literature 
published in the last decade on studies using multi-
plex technologies in identification of PTB biomarkers 
(search limited to biomarkers of spontaneous PTB only) 
in various biological samples collected from asymp-
tomatic and symptomatic women with PTB and intact 
membranes.
Methods
Study identification and selection
We sought studies that used multiplex assay techniques to docu-
ment potential biomarkers associated with PTB published between 
January 2005 and March 2014. The search was conducted with-
out language restriction in three electronic databases (PubMed, 
EMBASE and Web of Science) via OVID. All citations identified were 
downloaded into Mendeley electronic reference software (Mendeley 
Ltd., London, UK), and duplicates were excluded. Two independent 
reviewers screened the titles and abstracts of unique citations, and 
potentially relevant studies were selected for full-text reading; those 
that fulfilled the selection criteria were included in the review. Dis-
crepancies between the reviewers were discussed until consensus 
was reached; in case of persistent disagreement, a third reviewer was 
consulted.
The search was complemented by screening the reference lists 
of included studies. A search for unpublished studies was not per-
formed. The search strategy used the following terms and synonyms, 
adapted according to each database: (preterm birth OR preterm labor 
OR preterm delivery) AND (Multiplex OR protein array OR immunoas-
say OR antibody array OR antibody microarray OR protein microar-
ray OR biochip OR array OR microarray OR quantibody array OR multi 
analyte detection OR multi analyte profiling OR protein profiling OR 
biochip immunoassay OR Luminex OR xMAP OR ELISA array OR pro-
tein macroarray).
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Type of study
Studies that used any multiplex assay in search of multiple biomark-
ers for PTB and provided qualitative and/or quantitative information 
about biomarkers were considered eligible for inclusion. All types of 
study designs were considered acceptable, including cross-sectional, 
case-control, case-only, and cohort studies.
Population
Studies enrolling symptomatic or asymptomatic women at high or 
low risk for PTB of any gestational age  < 37 weeks, parity, race, age, or 
socioeconomic background were eligible for inclusion in the review.
Definition of multiplex assay
Multiplex assay was defined for the purpose of this review as simulta-
neous detection of more than one analyte in a single biological reac-
tion using a combination of specific antibodies with no documented 
cross-reactivity but compatible in combined assays.
Types of outcome
The target outcome was spontaneous preterm labor with intact mem-
branes leading to preterm delivery. The comparison groups included 
either term labor or preterm-matched gestational age.
Exclusion criteria
Studies were excluded if any of the following applied: (1) pregnancies 
with other associated complications, such as preeclampsia, intrau-
terine growth restriction, stillbirth, miscarriage, diabetes, abruptio 
placentae, or preterm premature rupture of membranes; (2) infection 
or chorioamnionitis associated with PTB; (3) animal-model stud-
ies; (4) genetic syndromes or diseases; (5) in vitro studies; (6) gene 
polymorphisms studies; (7) microbial detection as main objective of 
the study (microbiologic studies); (8) clinical trials, and (9) multiple 
pregnancies.
Data extraction
Two independent reviewers extracted data from the eligible stud-
ies using a standardized electronic data extraction form prepared 
for this review. The following data were collected: author; journal; 
year of publication; country where the study was conducted; study 
objective and design; total number of participants; number of cases 
and controls; patient characteristics at baseline including age, race, 
clinical symptoms, and risk of PTB; outcome phenotype definition; 
antenatal steroid administration; gestational age at the time of sam-
ple collection; source of biological sample; type of multiplex assay; 
method of validation of the results; and data analysis approach. 
Additional relevant assay-related information, such as processing, 
storage, and dilution of samples, was also collected, if available. The 
data collected were compared and discussed by the reviewers, and 
disagreements were resolved by consensus.
Assessment of the quality of the studies
Two independent reviewers assessed the quality of the included stud-
ies according to a set of parameters defined for this review using the 
QUADAS tool [21] and based on our group’s previous experience with 
this type of study [8, 12]. Differences in opinions between reviewers 
were resolved by consensus; in case of persistent disagreement, a 
third senior reviewer was consulted.
Grading criteria were as follows:
1. Grading of population characteristics
Well defined Detailed description of study group(s) (cases, con-
trols), ethics and consent procedure, and inclusion and exclu-
sion criteria. Inclusion criteria should have the definition of 
phenotype, estimation of gestational age, and gestational age at 
recruitment and at sample collection. Exclusion criteria should 
be explained in detail.
Adequately defined Brief description of study groups (cases, 
controls). Inclusion criteria should have the definition of pheno-
type, information as to how gestational age was assessed, and 
gestational age at recruitment and at sample collection. Exclu-
sion criteria should be explained in detail.
Poorly described or not reported Difficult to understand 
study design, study groups, or inclusion and exclusion criteria, 
and does not provide details listed above.
2. Grading quality of biomarker sampling
Well defined Detailed description of the sample type, sample 
collection protocol, timing of sample collection (gestational 
age), clinical status at sampling (symptomatic vs. asympto-
matic), pre-analytical processing of the sample, and storage 
conditions.
Adequately defined Brief description of the sample type, sam-
ple collection, and pre-analytical processing of the sample, but 
some aspects are missing or unclear.
Poorly described or not reported Most of the details are 
missing and/or difficult to understand as to how the sample 
collection and pre-analytical processing of the sample were per-
formed, mainly regarding storage and dilution.
3. Grading quality of multiplex analysis
Well defined Detailed description of sample processing 
and assay. Details included multiplex assay platform and 
its manufacturer, number of analytes, source of antibod-
ies and their cross-reactivity and compatibility, lower and 
upper levels of detection, standards used and methods for 
calculation of observed concentrations, details on assay per-
formance (intra-assay and inter-assay variabilities), and sta-
tistical analysis approaches, including control for multiple 
 comparisons.
Adequately defined Brief description of the sample pro-
cessing, multiplex assay, and analytical details as described 
above.
Poorly described or not reported Most of the details are miss-
ing and/or it is difficult to understand how the samples were 
prepared and proteomic analyses were performed.
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Data synthesis
Biomarkers were grouped according to the name of the identified pro-
tein of interest retrieved from the UniProt database, type of sample, 
and multiplex approach. We planned to pool the results of similar 
studies in a meta-analysis to assess the results of different multiplex 
analyses in biological samples from women with and without PTB.
Results
The search of three electronic databases yielded 3631 
unique citations, 3598 of which were excluded as irrel-
evant after title and abstract screening; 33 were selected 
for full-text reading. From those selected, 22 studies [19, 
22–42] that did not fulfill the selection criteria and one 
study [26] for which the full text could not be obtained 
after repeated attempts was excluded. Ten studies that 
used multiplex assay for identification of PTB biomark-
ers in maternal and/or fetal samples were included in the 
review. A process flowchart of study identification, selec-
tion, and inclusion is presented in Figure 1.
Main characteristics of the ten studies included in 
the present review are summarized in Table  1. These 
studies were conducted in seven developed countries 
and published between 2006 and 2013 in North Ameri-
can or European journals of obstetrics and gynecology or 
immunobiology, reflecting both clinical and basic science 
readership. There were four cohort studies [15, 20, 44, 46], 
five case-controls [14, 16, 17, 43, 45], and one cross-sec-
tional [18]. Although race/ethnicity plays a major role in 
biomarker disparity associated with PTB, only two studies 
reported on the ethnicity of the studied populations [17, 
20]. Gestational age (GA) at sample collection, an impor-
tant factor influencing biomarker association with PTB, 
was reported in all studies except one [43]; however, the 
missing information was obtained for this study through 
personal communication with the authors (Table 1). All 
studies reported a calculation of GA based on the last 
menstrual period corroborated by ultrasound dating in 
the second trimester. In nine out of the ten studies, the 
samples were collected from patients with symptomatic 
preterm labor, while in the remaining study, the samples 
were collected from asymptomatic pregnant women [45].
Biological samples
Fourteen sets of biological samples were analyzed. Three 
studies analyzed more than one biological sample [14, 
17, 20]. The majority of the samples were maternal blood 
(57.1%), either plasma or serum, followed by amniotic fluid 
(14.1%), fetal plasma, placenta, choriondecidua, and cervi-
cal fluid (7.2% each). Samples were collected during labor 
(69.2%), after delivery (18.1%), and, in one prospective 
cohort, between 24 and 26 weeks of gestation before the 
Unique citations identified
through electronic search
n=3631
Citations excluded after
screening titles and abstracts
n=3598
Citations selected
for full-text reading
n=33
Studies included in the review
n=10
Citations excluded after full-text reading
 n=23
No multiplex approach (specific immunoassays/mass
Inclusion of PPROM along with PTB
In-vitro study
Full text not available
No prediction of PTB (MIAC, neonatal infection,
descriptive results)
n=8
n=7
n=6
n=1
n=1
sprectrometry/microarray)
Figure 1: Flowchart of identification and selection of studies on preterm labor-related biomarkers using a multiplex protein assay. 
(PTB = Preterm birth, MIAC = microbial invasion of the amniotic cavity, defined as positive PCR and/or a positive amniotic fluid culture; 
PPROM = preterm premature rupture of membranes).
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onset of labor [45]. Seventy percent of the studies provided 
details on sample collection, preparation, and storage.
Details about sample size calculation were provided 
only by one paper [14]. An acceptable power calculation 
was not provided by any of the studies, likely due to either 
a lack of prior data for power calculation or the inability 
to generate power that would be able to detect signifi-
cant changes in multiple analyte concentrations among 
various groups. Sample size varied from 30 to 648 par-
ticipants, with most of the studies (76.9%) including fewer 
than 100 subjects comprising both cases and controls.
Type of multiplex assays used
The assays used in the selected studies are listed in 
Table  1. Forty percent of the studies used multiplexed 
assays based on Luminex technology (LabMAP, Luminex 
Corp, Austin, TX, USA) [47, 32, 24, 15], while FAST Slide 
protein microarray platform (Whatman Laboratories, 
Little Chalfont, Buckinghamshire, UK), Meso Scale Dis-
covery (MSD; Gaithersburg, MD, USA), Searchlight assay 
(Pierce Biotechnology Laboratory, Rockford, IL, USA), and 
Raybiotech assay (Norcross, GA, USA) were used by Brou 
et al. [17], Faupel-Badger et al. [44], Laudanski et al. [18], 
and Laudanski et al. [43], respectively. Only one study per-
formed validation of the multiplex assay [16], while the 
others referenced previous work or provided no details. 
The rationale for the assay choice was not explicitly pro-
vided in any of the studies.
Biomarkers associated with PTB
The panel of biomarkers analyzed between studies varied 
widely. The number of analytes reported ranged from 
two [46] to 44 [17]. From the total of 78 different biomark-
ers analyzed, 42 were associated with PTB (Table  2). 
The majority of the studied biomarkers were cytokines, 
chemokines, cytokine agonists or antagonists, receptors 
and soluble receptors, metalloproteinases and their inhib-
itors, growth and angiogenic factors, and adhesion mol-
ecules known to be involved in inflammatory pathways 
associated with PTB. Of the 31 PTB-related biomarkers 
assessed in maternal serum (see Table 1), the ones most 
frequently identified were RANTES [14, 15, 20] and IL-10 
[15, 17, 20] followed by MIP-1β, GM-CSF [15, 20], Eotaxin [17, 
43], and TNF-RI [15, 17]. Increased amniotic fluid ANGPT2 
was associated with PTB [17], and the levels of ICAM-1, 
IGF-I, IL-1β, IL-1Rα, IL-8, MCP-3, MIP-1α, PDGF-BB, TGF-α, 
TGF-β1, TIMP1, TNFα, TNFR-I, TNFR-II, and VEGF were Tab
le
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higher in fetal plasma from PTB cases than in fetal plasma 
from term delivery controls [17].
RANTES [14, 15, 20] and IL-10 [15, 17, 20] were found 
to associate with PTB by three studies. These articles 
were further analyzed for pooling their results in a meta-
analysis. However, we could not perform a meta-analysis 
because of major differences in the biological samples and 
study populations. Tsiartas et al. [15] and Holst et al. [20] 
used the same biomarker panel (27-plex), and the assays 
were performed by the same laboratory. Both studies 
reported an association between RANTES in various bio-
logical compartments and latency in the onset of preterm 
labor. Holst et al. [20] reported that RANTES levels in the 
amniotic and cervical fluids were significantly associ-
ated with delivery within 7 days, while Tsiartas et al. [15] 
found that high levels of maternal serum RANTES and 
short cervical length were significant to the prediction of 
spontaneous preterm delivery within 7 days. In the third 
work, Hamilton et al. [14] reported that RANTES increased 
in plasma from preterm in-labor women compared to 
preterm but not in labor; however, no differences were 
reported between PTB and normal term birth samples. 
Similarly, there were differences in the types of samples 
and phenotypes of the outcomes reported by the three 
studies that measured IL-10 [15, 17, 20], which also pre-
vented us from pooling the results into a meta-analysis. 
In a retrospective cohort study, Brou et  al. [17] reported 
decreased IL-10 in maternal plasma in PTB compared to 
normal term births. Tsiartas et al. [15] found higher mater-
nal serum IL-10, whereas Holst et  al. [20] reported an 
increase in both cervical and amniotic fluids IL-10 associ-
ated with delivery within 7 days in women with PTB com-
pared to those women who did not deliver within 7 days.
A complete list of the biomarkers, frequency of 
testing, and the distribution according to the pathophysi-
ologic pathway is provided in Table 1.
Quality assessment
As shown in Figure 2, most of the studies included in the 
review (8/10) had a well-defined study population [15–18, 
20, 46, 44, 45]. Only two studies received a low-quality 
grading because of poor description of the characteris-
tics of the sample population [14, 43]. In five articles, the 
sample collection and preparation were well described 
[15, 17, 18, 20, 45]. Sample collection and management 
were adequate in four other studies [16, 46, 44, 43], and 
one article provided only a summary description [14]. The 
assay methodology was well defined in five studies [15, 
17, 18, 20, 45], whereas two studies [16, 46] were graded Ta
bl
e 2
 (
co
nt
in
ue
d)
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of adequate quality, and three were judged to be of poor 
quality [14, 43, 44].
Discussion
PTB is a complex syndrome characterized by pathways 
with interacting biomarkers [47, 48]. In this review, we 
examined multiplex assays where multiple biomarkers 
were studied simultaneously in the same sample. We 
identified ten eligible studies that analyzed 74 biomarkers 
and identified 42 dysregulated biomarkers associated with 
PTB. Most of these studies recruited European-American 
and African-American populations. Several biomarkers 
were found to be associated with PTB in maternal plasma/
serum samples in more than one study, and RANTES 
and IL-10 emerged as potential candidates for further 
evaluation and validation studies with similar methodo-
logical approaches. However, criteria for performing a 
meta-analysis were not met, as none of the biomarkers 
were replicated in additional samples/studies by the same 
investigators or by other investigators following the same 
approach, population, and outcome. We have chosen not 
to discuss biomarkers reported in tissue-based studies 
as their usefulness in predicting PTB in clinical speci-
mens has yet to be evaluated. Accordingly, this system-
atic review also concludes that, at present and based on 
reported findings, no single or combination of biomarkers 
can be used to predict PTB risk.
Unlike the findings from our two previous system-
atic reviews [8, 12], the multiplex studies included in this 
Population
Biomarker
Multiplex assay 3 2
Poor Adequate Well defined
5
54
0 8
1
2
Figure 2: Quality assessment of the ten multiplex assay studies on 
spontaneous preterm birth-related biomarkers.
review had an overall better design and quality of report-
ing. Most of these studies were published fairly recently 
(between 2006 and 2013), and it is encouraging that a 
follow-up or replication study can be performed easily as 
the limitations are fewer and easier to address. However, 
many of the methodological issues reported in the afore-
mentioned prior reviews still persist, especially with 
respect to study design, hindering PTB biomarker discov-
ery. We highlight below some of these concerns.
All reports included in this review defined the studied 
outcome phenotype as spontaneous PTB. However, defi-
nition of this phenotype still remains as an enigma in 
PTB research due to the lack of standard and established 
definitions used in biomarker discovery and clinical trials. 
Recent reports highlighted the urgent need for defining 
PTB phenotypes [7, 49, 50]. A gold standard is yet to be 
developed, and investigators are still using their own cri-
teria for phenotype definition.
One key area identified by this report is the hetero-
geneity in the selection of biomarkers. Two major criteria 
used by investigators in biomarker panel selection led to 
a high diversity of biomarkers evaluated in a relatively 
small number of studies: (1) investigation of a specific 
pathophysiologic pathway of PTB and (2) convenience in 
using a predefined assay. Just like any other “candidate” 
marker studies, bias is introduced when selecting the 
panel by either of these methods. Although there are no 
proper solutions for eliminating bias in candidate marker 
selection, incorporating biomarkers from all known and 
reported pathways, rather than skewing the selection of 
markers by choosing from “desired” pathways, is not the 
best approach to minimize such biases. Selection of panels 
based on convenience and without proper rationale or bio-
logical relevance is unlikely to yield reproducible data.
Multiplex assays have emerged as important tools for 
screening disease-related biomarkers. Numerous types of 
multiplex arrays are available on the market from different 
manufacturers, differing by number and type of cytokines 
included in the array, sensitivity in detection, the variety 
of antibodies and standards used in the kits, and incuba-
tion time [51]. In our review, 40% of the studies used the 
Luminex technology assay (LabMAP) [52]. Using a multi-
plex bead array, Luminex assays facilitate simultaneous 
cytometric quantitation of multiple immune mediators 
(i.e. cytokines) in solution by capturing these to spec-
trally distinct beads with the distinct advantages of higher 
throughput, smaller volume (as little as 12 μL per sample) 
of various biological samples (e.g. maternal serum, cervi-
cal or vaginal fluid), and lower costs [53]. However, one of 
the included studies applied the FAST Slide protein micro-
array platform [17]. The main advantage of this technology 
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is that the matrix retains arrayed proteins in a near-quan-
titative fashion that translates into antibody arrays with 
sensitivity down to antigen concentrations of 1 pg/mL. 
Faupel-Badger et al. [44] used MSD multiplex microarray, 
which is based on MULTI-ARRAY® technology, a propri-
etary combination of electrochemiluminescence detec-
tion and patterned arrays. The instrument (Sector Imager 
2400) that is used to detect signals from the assay uses 
highly efficient custom-designed optics and ultrasensitive 
photo detectors to collect and quantitatively measure light 
emitted from the microplates. In 2006, Laudanski et  al. 
[18] used a Searchlight assay which is a multiplexed sand-
wich enzyme-linked immunosorbent assays (ELISAs) with 
imaging system based on a cooled charge-coupled device 
camera which detects the chemiluminescent signal at each 
spot in the array. In 2012, Laudanski et al. [43] used a mul-
tiplex-based platform from Raybiotech for simultaneous 
quantitative measurement of different proteins from one 
sample, which has the advantage of being read by most 
of the conventional array fluorescent plate readers avail-
able on the market. Considering the diversity in described 
assays, it appears that the choice in using one particular 
assay may be driven by several decision factors, such as 
a researcher’s familiarity with a specific PTB pathway, a 
particular research question, the type of biological sample 
available, convenience, and financial feasibility.
Other areas of heterogeneity among studies included 
study design, type of sample used for biomarker discov-
ery, timing of sample collection, and inclusion of asymp-
tomatic or symptomatic women. The methodology of 
statistical analysis employed introduced yet another field 
of heterogeneity. Many of these studies lacked reporting 
on confounding variables and control for multitudes of 
covariates. Therefore, results may also have been impacted 
by association by chance due to analysis confounded by 
multiple testing or lack of adequate power. Many of these 
issues were identified and discussed in detail in our prior 
systematic reviews. Readers are encouraged to review the 
guidelines and checklists in our previous publications that 
apply to studies using multiplex assays [8, 12]. Moreover, 
based on the above-detailed issues in identifying PTB bio-
markers through multiplex approaches, we suggest a few 
guidelines to consider prior to initiation of future studies.
Suggested approaches for multiplex assay 
discovery and future validation strategies
Success of a biomarker study is directly dependent on the 
quality of specimen collection and how it is processed 
until assay, considering appropriate preservatives and 
storage conditions to avoid any variations in the biomarker 
level and integrity. Reporting should include a detailed 
description of these procedures, as well as sensitivity and 
specificity of the assay, and inter- and intra-assay varia-
tions should be considered and reported. Sampling is 
dependent upon study design and other rationale estab-
lished prior to collecting, and biological specimens that 
are easy to obtain should be chosen to assess the risk of 
PTB. The appropriate sample size of required cases and 
controls should be calculated to properly evaluate the 
association of biomarkers alone and in combination, and 
this parameter depends on the number of analytes under 
investigation. Thus, sample size calculations for explora-
tory factor analysis should be employed. While no optimal 
cases-to-controls ratio exists, a higher ratio of controls 
to cases would result in greater study power. Subject-
to-variable ratios from 20:1 to 100:1 are not uncommon. 
When the number of biomarkers is large compared to the 
number of cases and controls, chance associations may be 
uncovered and hinder progress. Statistical analysis and 
proper selection of analytical methods should address the 
hypothesis and objectives established prior to the study 
and the study design. We recommend the following steps: 
(1) perform statistical assessment of distribution of bio-
marker concentration (normal or non-normal); (2) select 
appropriate form of presenting data based on distribution 
[i.e. mean±standard deviation (SD), median (interquartile 
range)]; (3) identify potential confounding factors (e.g. 
clinical and demographic) and adjust for confounders; 
and (4) adjust for multiple testing. If the discovery set 
has sufficient power to project biomarker combinations, 
the interference on quantitation should be evaluated as 
well. For example, if the discovery multiplex assay evalu-
ated a large number of potential markers and the results 
indicate that only a small number are associated with PTB 
risk, it might make sense to only test the smaller number 
in future validation efforts. In this context, a prospective 
validation using a new, independent set of specimens is 
also required to confirm the performance of the biomarker 
panel. During this validation, it is not appropriate to add 
additional biomarkers or adjust the predictive algorithm; 
if such modifications are required to improve the predic-
tion, then a new prospective effort utilizing an independ-
ent specimen set is required to validate the modifications.
The mathematical algorithm, which combines the 
assay results of each biomarker into a single output predic-
tive of PTB, is as important as the biomarkers of a predic-
tive biomarker combination. Prior to the validation studies 
using this algorithm, a sample set independent of those 
used in discovery phase can be tested for the optimization 
of the algorithm. Indeed, even if the biomarker set includes 
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numerous proteins, these measurements should be com-
bined into a single risk estimate (similar to combination of 
multiple markers to provide a single estimate for the risk of 
other diseases). Multi-marker assays developed in this way 
are amenable to traditional validation methods.
The rationale behind biomarker research assumes 
that multiple biomarkers perform better than a single 
biomarker for assessing PTB risk. Success of biomarker 
studies depends on the ability to identify those biomark-
ers that predict PTB from within the larger panel of bio-
markers studied. These biomarker sets may be difficult to 
identify unless statistical approaches allow for the pos-
sibility that each biomarker of the set is by itself a poor 
predictor, and perform well only in combination. Negative 
results of studies to date could have been hindered by a 
lack of this type of analysis.
Finally, appropriate reporting of data involves follow-
ing all the listed guidelines throughout the study. Report-
ing should be based on the hypothesis tested and match 
the studied objectives. Inclusion of study limitations will 
help the reader better interpret reported findings and 
address such limitations in future studies.
In summary, multiplex assays provide promising 
technological advancement in identifying biomarkers of 
PTB over other approaches that our group has previously 
systematically reviewed. Understanding the limitations 
of existing reports and designing studies, following the 
criteria detailed above may facilitate the identification of 
better biomarkers for screening and prediction of PTB.
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